ZTABS builds natural language processing systems for Seattle companies that need to extract meaning, structure, and intelligence from unstructured text at scale — biotech and life sciences NLP that processes clinical trial documents, FDA submissions, scientific literature, and patient records to accelerate drug development timelines by automating the reading and analysis of thousands of documents that currently require teams of medical writers, regulatory specialists, and clinical research associates spending months on manual review, medical entity recognition systems that identify drugs, diseases, genes, proteins, adverse events, and clinical endpoints in unstructured medical text with 95%+ accuracy — enabling pharmaceutical companies to automatically extract safety signals from adverse event reports, identify potential drug interactions from scientific literature, and build structured knowledge graphs from decades of unstructured research documents, and regulatory document intelligence that transforms 500-page FDA submission packages, clinical study reports, and investigator brochures into searchable, cross-referenced knowledge bases where regulatory teams can instantly find precedent language, identify consistency issues across documents, and generate first drafts of new submissions using validated templates built from historical approvals.
NLP development in Seattle serves the city's growing life sciences and biotechnology sector — an industry that generates enormous volumes of unstructured text (clinical trial reports, FDA submissions, scientific publications, patent filings, adverse event reports, and medical records) that must be read, understood, analyzed, and acted upon by human experts whose time is the primary bottleneck in drug development timelines. Seattle NLP and biotech landscape: Seattle's biotechnology sector has grown dramatically — the city and surrounding region are now home to 800+ life sciences companies, including major operations from Bristol-Myers Squibb, Sanofi, Adaptive Biotechnologies, Seagen (now Pfizer), and Seattle Genetics. The Fred Hutchinson Cancer Center, University of Washington Medical Center, and Seattle Children's Hospital generate world-class clinical research. This life sciences concentration creates intense demand for NLP — the technology that bridges the gap between unstructured human-written text and the structured data that computational systems need.
The NLP challenge in biotech: a single clinical trial generates 50,000-100,000 pages of documentation — clinical study reports, investigator brochures, informed consent forms, case report forms, statistical analysis plans, safety reports, and regulatory submissions. A pharmaceutical company running 20 concurrent trials manages 1-2 million pages of active documentation. Reading and analyzing this documentation is the work of hundreds of specialized professionals — medical writers, regulatory affairs specialists, pharmacovigilance analysts, clinical research associates, and biostatisticians — whose combined labor represents a significant portion of the $2.6 billion average cost to bring a new drug to market. NLP can't replace these experts — the regulatory and safety stakes are too high for fully autonomous AI decision-making in pharmaceutical development.
But NLP can dramatically accelerate their work: automatically extracting structured data from narrative documents (adverse events from safety reports, endpoints from clinical study reports, regulatory requirements from FDA guidance documents), identifying relevant information across thousands of documents (finding every mention of a specific adverse event across all trials for a drug, locating precedent regulatory language from previous approvals), detecting inconsistencies and errors (identifying discrepancies between a clinical study report and its statistical analysis plan, flagging missing safety information in regulatory submissions), and generating first drafts (creating initial drafts of regulatory documents using templates and language validated from previous successful submissions — drafts that expert human reviewers can refine rather than write from scratch). NLP technology landscape: modern NLP has been transformed by large language models and transformer architectures.
For biotech NLP in Seattle, the technology stack typically includes: pre-trained biomedical models (BioBERT, PubMedBERT, BioGPT — language models pre-trained on biomedical literature that understand medical terminology, drug names, disease classifications, and scientific writing conventions better than general-purpose models), named entity recognition (NER) systems (models trained to identify and classify specific entities in text — drugs, diseases, genes, proteins, adverse events, dosages, clinical endpoints — using sequence labeling architectures (BiLSTM-CRF, transformer-based NER) trained on biomedical entity corpora), relation extraction (systems that identify relationships between entities — drug-disease relationships (treatment, side effect, contraindication), drug-drug interactions, gene-disease associations — critical for building knowledge graphs from unstructured literature), document classification (categorizing documents by type, topic, regulatory relevance, and priority — enabling automated routing, filing, and priority triage of incoming documents), and text generation (LLM-powered generation of regulatory documents, summaries, and reports — constrained by templates and validated against source documents to ensure accuracy and compliance).
Seattle NLP development demand spans clinical trial operations, regulatory affairs, pharmacovigilance, and scientific research — each with stringent accuracy and compliance requirements.
Clinical Trial NLP: clinical study report analysis (NLP systems that process clinical study reports (CSRs) — the primary documents describing clinical trial methods, results, and conclusions — for Seattle: CSR analysis includes: endpoint extraction (automatically extracting primary and secondary endpoint results, statistical analysis details, confidence intervals, and p-values from narrative text — structuring this data into standardized formats for regulatory submission and cross-trial comparison), safety data extraction (identifying and classifying adverse events, serious adverse events, and adverse events of special interest from safety narrative sections — correlating adverse events with patient demographics, dosing, and concomitant medications), and protocol deviation detection (identifying deviations from the planned protocol — enrollment violations, dosing errors, visit window violations — by comparing CSR narrative against the original protocol document)), patient narrative processing (NLP systems that process individual patient narratives — detailed clinical accounts of patients who experienced serious adverse events — for Seattle: patient narrative NLP includes: event timeline extraction (building chronological timelines from narrative text — when symptoms began, when treatment was administered, when the event resolved or became ongoing), causality signal detection (identifying language that suggests causal relationships between the study drug and adverse events — terms like "possibly related," "considered unlikely," "cannot be ruled out" have specific regulatory meaning), and cross-narrative analysis (comparing patient narratives across trials to identify patterns — similar adverse events occurring at similar timepoints across different patient populations may indicate a safety signal))).
Regulatory Affairs NLP: FDA submission processing (NLP systems for preparing and reviewing FDA regulatory submissions — for Seattle: regulatory NLP includes: Common Technical Document (CTD) analysis (parsing Module 2 (summaries), Module 4 (nonclinical study reports), and Module 5 (clinical study reports) to extract key information, verify cross-references, and identify gaps or inconsistencies — CTD submissions can span 100,000+ pages across hundreds of individual documents), FDA guidance document analysis (processing FDA guidance documents, Federal Register notices, and advisory committee meeting minutes to identify requirements, recommendations, and precedent decisions relevant to a specific drug development program), and regulatory language generation (generating first drafts of regulatory documents — Prescribing Information (PI), Patient Package Inserts (PPI), and Investigator Brochures (IB) — using templates derived from previously approved documents with appropriate modifications for the specific drug and indications)).
Pharmacovigilance NLP: adverse event processing (NLP systems for pharmacovigilance — the monitoring of drug safety after approval — for Seattle: pharmacovigilance NLP includes: Individual Case Safety Report (ICSR) processing (extracting structured data from narrative adverse event reports — patient demographics, drug information, adverse event description, outcome, and causality assessment — from reports submitted in multiple formats (MedWatch forms, hospital records, patient letters, call center transcripts)), signal detection (analyzing large volumes of adverse event reports to identify safety signals — unexpected patterns of adverse events, increased frequency of known adverse events, or new drug interactions — using statistical and NLP methods to distinguish genuine signals from reporting noise), and literature monitoring (automatically scanning published medical literature for safety-relevant information about marketed drugs — identifying case reports, observational studies, and meta-analyses that may contain new safety information))).
Scientific Research NLP: literature analysis (NLP systems for analyzing scientific publications — for Seattle: literature NLP includes: systematic review automation (accelerating systematic literature reviews by automatically screening thousands of publications for relevance based on inclusion/exclusion criteria — reducing screening time from weeks to hours), knowledge graph construction (building structured knowledge graphs from unstructured scientific literature — entities (drugs, diseases, genes, proteins, pathways) and relationships (treats, causes, inhibits, activates) extracted from publications and organized into queryable databases), and competitive intelligence (monitoring scientific publications and conference presentations to track competitor drug development programs — identifying which diseases competitors are targeting, which mechanisms they're pursuing, and which clinical trials they're conducting)).
Our NLP development for Seattle delivers production-grade text analysis systems designed for the accuracy, auditability, and regulatory requirements of the life sciences industry.
Phase 1 — Corpus Analysis and Model Strategy (2-3 weeks): understanding the text: corpus characterization (analyzing the client's document corpus — document types, volumes, formats, languages, and text characteristics — for Seattle: biotech document corpora have specific characteristics that affect NLP strategy: highly specialized vocabulary (medical terminology, drug names, disease classifications), structured narrative conventions (CSRs follow ICH E3 guideline structure, FDA submissions follow CTD format), and strict formatting requirements that provide structural cues for NLP systems), entity and relationship taxonomy (defining the entities and relationships the NLP system must identify — for Seattle: entity taxonomies must align with established medical ontologies (MedDRA for adverse events, WHO Drug Dictionary for medications, SNOMED CT for clinical findings, ICD-10 for diseases) — alignment with these standards is critical for regulatory acceptance and interoperability), model selection (choosing the right NLP approach for each task — for Seattle: biotech NLP typically uses a combination of: pre-trained biomedical transformers (BioBERT, PubMedBERT) fine-tuned on the client's specific document types, rule-based systems for pattern extraction where rules are well-defined (dosage extraction, date parsing, regulatory reference identification), and LLM-based systems (GPT-4, Claude) for tasks requiring broader reasoning (document summarization, regulatory language generation, inconsistency detection)), and evaluation strategy (defining how NLP system accuracy will be measured — for Seattle: evaluation must include expert human review — NLP accuracy in biotech is measured against domain expert annotation, not against other NLP systems — evaluation metrics include precision (of the entities the system identified, what percentage were correct?
), recall (of the entities that exist in the text, what percentage did the system find?), and F1 score (the harmonic mean of precision and recall))).
Phase 2 — NLP System Development (6-10 weeks): building the text analysis pipeline: training data preparation (creating annotated training datasets — for Seattle: biotech NLP training data requires expert annotation — medical writers, pharmacovigilance specialists, or regulatory affairs professionals must annotate documents with the correct entities, relationships, and classifications — we develop annotation guidelines collaboratively with domain experts and use multi-annotator agreement metrics (Cohen's kappa) to ensure consistency — typical training datasets: 200-500 annotated documents for named entity recognition, 500-1,000 annotated document pairs for relation extraction), model training and optimization (training NLP models on the annotated data — for Seattle: training typically involves: base model selection (starting from BioBERT or PubMedBERT rather than general BERT — the biomedical pre-training provides a significant accuracy advantage for medical text), task-specific fine-tuning (fine-tuning the base model on the client's annotated data — learning the specific entity types, relationship types, and document formats relevant to the client's use case), and hyperparameter optimization (systematically testing different training configurations to maximize accuracy on the held-out evaluation set)), pipeline integration (connecting NLP models into end-to-end processing pipelines — for Seattle: biotech NLP pipelines typically include: document ingestion (handling multiple input formats — PDF, Word, XML, structured data exports from clinical trial management systems), pre-processing (text extraction, section detection, table parsing, reference resolution), NLP analysis (entity recognition, relation extraction, classification, summarization), post-processing (entity normalization against medical ontologies, confidence scoring, conflict resolution), and output (structured data export to downstream systems — databases, knowledge graphs, regulatory submission tools, dashboard visualizations)), and human-in-the-loop (designing interfaces for human expert review and correction — for Seattle: all biotech NLP outputs must be reviewable by domain experts before being used in regulatory submissions or safety decisions — the system must make it easy for experts to verify, correct, and approve NLP outputs — and corrections must feed back into the system to improve future accuracy)).
Phase 3 — Validation and Deployment (2-4 weeks, then ongoing): ensuring accuracy for regulated environments: validation (rigorous accuracy validation against held-out test datasets — for Seattle: validation for life sciences NLP must follow 21 CFR Part 11 guidelines for electronic records — validation includes: accuracy measurement (precision, recall, F1 on each entity type and relationship type), edge case analysis (identifying text patterns where the system underperforms and documenting known limitations), comparison against baseline (measuring improvement over the previous manual process — speed improvement and accuracy comparison), and expert review (domain experts reviewing a statistically significant sample of NLP outputs to validate accuracy claims)), deployment (deploying the NLP system into production — for Seattle: deployment must meet life sciences IT requirements: GxP-compliant hosting (AWS GovCloud or validated private cloud), audit trail (logging every NLP decision with input, output, model version, and confidence score), access control (role-based access limiting who can view, modify, and approve NLP outputs), and data security (encryption at rest and in transit, HIPAA compliance for patient data, SOC 2 certification)), and continuous improvement (monitoring NLP accuracy in production and retraining as needed — for Seattle: NLP systems in biotech require ongoing maintenance as: new drugs and diseases enter the lexicon, regulatory requirements and document formats change, edge cases discovered in production require additional training data, and model drift (gradual accuracy degradation) is detected through periodic accuracy audits)).
Free consultation — no commitment required.
A Seattle biotech company with 6 active clinical programs (3 in Phase II, 2 in Phase III, 1 filing NDA) was drowning in clinical documentation. The company's 14-person regulatory affairs and medical writing team was responsible for managing approximately 340,000 pages of active clinical documentation — clinical study reports, investigator brochures, regulatory submissions, safety reports, and correspondence with FDA. Specific documentation challenges: cross-document consistency — each drug development program generated 50,000-80,000 pages of documentation across multiple document types. Information stated in one document (e.g., a specific adverse event rate in the clinical study report) must be consistent with the same information stated in other documents (the investigator brochure, the NDA summary, the prescribing information draft). With 340,000 pages across 6 programs, checking cross-document consistency manually was practically impossible — yet inconsistencies in regulatory submissions could trigger FDA information requests that delayed approval by months.
The company estimated that 15-20% of FDA information requests on their previous submissions were related to consistency issues that could have been caught with better document review. Safety signal extraction — the company's pharmacovigilance team received approximately 2,800 Individual Case Safety Reports (ICSRs) per quarter across their 6 active programs. Each ICSR contained a narrative description of an adverse event — typically 200-800 words of unstructured medical text describing the patient's experience. Processing each ICSR required: reading the narrative, identifying the adverse event (coded to MedDRA terminology), assessing severity and seriousness, determining relatedness to the study drug, and entering structured data into the safety database. This manual processing took an average of 25 minutes per report — consuming 1,167 hours per quarter (approximately 3 FTEs dedicated full-time to ICSR processing).
Regulatory document generation — preparing NDA submission modules required medical writers to draft regulatory documents following strict format and content guidelines (ICH CTD format). For a Phase III program preparing for NDA submission, the medical writing team spent approximately 8 months preparing the submission package — much of which involved adapting language from the clinical study report into the required regulatory formats, ensuring consistency with previous submissions, and verifying that all required content elements were included. The team estimated that 40-50% of medical writing time was spent on mechanical transformation tasks (reformatting, cross-referencing, consistency checking) rather than substantive scientific writing.
We built a clinical document intelligence platform over 14 weeks — an NLP-powered system that automated document processing, consistency checking, and draft generation for the company's regulatory and medical writing teams.
Document Processing Pipeline: ingestion (the system accepted documents in multiple formats: PDF (scanned and native), Word, and XML (eCTD format) — for scanned PDFs, OCR was performed with medical-dictionary-enhanced accuracy — documents were automatically classified by type (CSR, IB, safety report, submission module) and associated with the correct drug program), section detection (using the known structural conventions of clinical documents — ICH E3 for CSRs, ICH M4 for CTD modules — the system automatically segmented documents into sections and subsections — enabling section-level analysis and cross-document section comparison), and entity extraction (the core NLP capability — extracting structured entities from unstructured text: adverse events (identified and coded to MedDRA Preferred Terms — handling synonyms, abbreviations, and contextual descriptions — "the patient experienced a severe headache" → MedDRA PT: "headache", severity: "severe"), medications (drugs identified and coded to WHO Drug Dictionary — including study drug, concomitant medications, and rescue medications — handling brand names, generic names, abbreviations, and dosage forms), clinical endpoints (primary and secondary endpoints extracted with associated statistical results — effect size, confidence intervals, p-values, and statistical methods), patient demographics (age, sex, race, weight, medical history extracted from patient narratives and demographic summaries), and laboratory values (laboratory test results extracted with test name, value, units, normal range, and clinical significance assessment)).
Cross-Document Consistency Engine: the consistency engine compared information across documents within a drug program: numerical consistency (the same adverse event rate, patient count, endpoint result, or statistical value stated in multiple documents must be identical — the engine identified every instance of a specific numerical claim across all documents in a program and flagged discrepancies — example: "Treatment-related adverse events occurred in 23% of patients" in the CSR vs.
"Treatment-related adverse events occurred in 24% of patients" in the NDA summary — a 1% discrepancy that could trigger an FDA information request), terminology consistency (medical terminology must be used consistently across documents — the same adverse event must be coded to the same MedDRA term, the same medication must be referenced by the same name, and the same clinical endpoint must be described using the same language — the engine identified terminology variations and flagged them for review), and structural completeness (regulatory submissions must include specific content elements — the engine checked each document against its required structure (CSRs against ICH E3, NDA modules against ICH M4) and identified missing sections, incomplete sections, or sections that didn't meet minimum content requirements).
ICSR Processing Automation: automated extraction — the system processed ICSR narratives automatically: narrative parsing (reading the 200-800 word adverse event narrative and extracting structured data fields: adverse event description (coded to MedDRA), onset date, duration, severity, seriousness criteria (death, life-threatening, hospitalization, disability), outcome (recovered, recovering, not recovered, fatal, unknown), and relatedness assessment (the narrative's stated assessment of whether the event was related to the study drug)), quality checks (the extracted data was cross-checked against other fields in the ICSR: did the MedDRA code match the narrative description? was the seriousness assessment consistent with the seriousness criteria? was the onset date within the treatment period?
), and human review workflow (every automated extraction was presented to a pharmacovigilance analyst for review — the analyst saw the original narrative alongside the system's extracted data, with confidence scores for each field — the analyst could accept, modify, or reject each extraction — corrections fed back into the training data for model improvement).
Regulatory Document Generation: template-based generation — the system generated first drafts of regulatory documents using validated templates: template library (templates derived from the company's previously approved submissions — capturing the structure, content requirements, and language conventions that FDA reviewers expected), data population (templates automatically populated with data extracted from the clinical study report — adverse event tables, efficacy results, demographic summaries, and safety narratives — drawn from the structured data in the document intelligence platform), language generation (for narrative sections that couldn't be mechanically populated — the system used GPT-4 constrained by the template structure and validated against source documents — generating first-draft language that medical writers could refine rather than write from scratch), and track changes output (generated drafts were produced with full traceability — every sentence linked to its source document and specific section — medical writers could verify every claim against the original source data).
The platform deployed across all 6 active drug programs after a 4-week validation period. Quantitative Results (first 12 months): ICSR processing — processing time: reduced from 25 minutes to 6 minutes per report (76% time reduction — the system performed initial extraction in seconds; the 6 minutes represented human review and approval time). Accuracy: the system's initial extraction was accepted without modification in 88% of cases (across all data fields — MedDRA coding: 92% accuracy, severity assessment: 94% accuracy, relatedness assessment: 81% accuracy — relatedness was the most subjective field and required human judgment most often). Capacity impact: the same 2-person pharmacovigilance team processed 3,200 ICSRs per quarter (up from 2,800) while spending 60% less time on mechanical processing — freeing time for signal detection analysis and safety trend evaluation. Cross-document consistency — the consistency engine identified 847 inconsistencies across the company's 340,000-page document corpus in its initial analysis.
Breakdown: 312 numerical discrepancies (adverse event rates, patient counts, and endpoint results that differed between documents), 289 terminology variations (the same adverse event or medication referenced differently across documents), and 246 structural gaps (missing or incomplete content elements in regulatory submissions). Of the 847 identified inconsistencies: 623 were confirmed genuine issues that required correction (73.6% precision). 224 were false positives (the engine flagged differences that were intentional or acceptable in context). The 623 genuine inconsistencies would have previously been discovered during FDA review — each potentially triggering an information request that delays approval. The company's regulatory affairs team estimated that resolving these inconsistencies proactively saved 4-6 months of cumulative delay across their active programs. Regulatory document generation — the document generation system reduced first-draft preparation time for NDA submission modules by an estimated 55%.
For the company's Phase III program preparing for NDA submission: total medical writing time: reduced from 8 months to 4.5 months (44% reduction). Specifically: Module 2.5 (Clinical Overview): first draft generated in 3 days (previously 4 weeks of medical writer time). Module 2.7 (Clinical Summary): first draft generated in 5 days (previously 6 weeks). Module 5 appendices (individual study reports): structured and cross-referenced automatically (previously 3 weeks of manual organization). The medical writers reported that the generated drafts required significant scientific editing but that the mechanical work (formatting, cross-referencing, table generation, consistency with source data) was handled accurately by the system — allowing them to focus on the substantive scientific content that required their expertise. Financial Impact: pharmacovigilance efficiency — $280,000 annual labor savings (equivalent of 2 FTEs of processing time reallocated to higher-value safety analysis work).
Regulatory timeline acceleration — the company estimated that proactive consistency correction and faster document generation would accelerate their NDA submission by 3-4 months. At the company's estimated cost of delay ($2.5 million per month of delayed market entry for their lead program), this represented $7.5-10 million in accelerated revenue. Medical writing efficiency — $420,000 annual savings (equivalent of 3 FTEs of mechanical medical writing work automated). Total estimated annual value: $8.2-10.7 million (including accelerated revenue from faster NDA preparation). Platform development cost (ZTABS): $520,000 (14-week build). Annual operating cost: $96,000 (LLM API costs + infrastructure + model retraining). Year 1 ROI: 15.8:1 (using the conservative $8.2M value estimate).
Beyond positive/negative — aspect-based sentiment analysis that tells you exactly what customers love or hate about specific features, with domain-specific calibration.
Custom NER models trained on your domain to extract people, organizations, products, dates, amounts, and domain-specific entities from any text.
Multi-label document classification into your custom taxonomy with confidence scores and automated routing based on classification results.
Extractive and abstractive summarization of long documents, meeting transcripts, research papers, and customer conversations — preserving key information.
Identify and extract relationships between entities in text — connecting people to organizations, products to features, or symptoms to diagnoses.
Cross-lingual models that work across 100+ languages, with specialized fine-tuning for your target languages and domains.
Seattle NLP providers for life sciences include specialized biotech AI companies, academic spinouts, large IT consulting firms, and general NLP/AI development shops. (1) Specialized biotech NLP companies (Linguamatics/IQVIA, Saama Technologies) — purpose-built for life sciences but expensive (enterprise licensing $200K-$500K/year), inflexible (limited customization to specific document types and workflows), and focused on specific niches (pharmacovigilance or literature review but not end-to-end document intelligence). (2) Academic spinouts (UW NLP lab, FHCC informatics) — cutting-edge research but limited production engineering capability and long engagement timelines. (3) Large IT consulting firms (Accenture, Deloitte) — comprehensive capabilities but high cost ($400-800/hr), slow delivery, and generalist teams that lack deep NLP specialization. (4) General AI/NLP development shops — strong NLP skills but lacking life sciences domain expertise and regulatory compliance knowledge.
ZTABS combines NLP engineering expertise with life sciences domain knowledge and regulatory compliance experience — building systems that meet both accuracy requirements and regulatory validation standards.
NLP development for Seattle biotech varies by document volume, entity complexity, and regulatory requirements. Focused NLP system (single document type, defined entity set, 8-10 weeks): $180,000-$350,000. Document intelligence platform (multiple document types, cross-document analysis, generation, 12-16 weeks): $350,000-$650,000. Enterprise NLP platform (full document lifecycle, regulatory compliance, GxP validation, 16-24 weeks): $600,000-$1,200,000. Ongoing: $6,000-$15,000/month for model monitoring, retraining, and infrastructure. ZTABS delivers at $230-330/hr — NLP engineers with biomedical model expertise and life sciences regulatory compliance experience.
Verified reviews from real client engagements — sourced from our public testimonial archive and Clutch profile.
My experience is throughout positive. Communication, service, the short response times and the flawless execution of a challenging topic was absolutely great. ZTABS is definitely my first choice again.
Christian Neff
Bank Software Advisory · Bank Software Advisory
Fintech
Fantastic Agency! I couldn't fault them even if I tried. They always go above and beyond to meet your expectations and always produces quality work. Thank you ZTABS.
Stephanie Kal
CEO · Beauty Finder Australia
Marketplace
It has been great working with ZTABS. They bounce off the ideas along the way. Amazing Experience.
Joel Rowe
CEO · Drill Quoter
Marketplace
We don't just contract. We ship and operate our own software. 23 products in production.
Common questions about NLP & text analytics for Seattle businesses
For well-defined extraction tasks (adverse event identification, medication extraction, dosage parsing), modern biomedical NLP achieves 90-96% accuracy — comparable to human inter-annotator agreement (the rate at which two human experts agree on the same text). For more subjective tasks (causality assessment, severity grading, clinical significance determination), NLP accuracy is lower (75-85%) and human review remains essential. Our approach: NLP handles the high-volume extraction work at 90%+ accuracy, and human experts review, correct, and approve the outputs — combining machine speed with human judgment.
ZTABS is a remote-first NLP & text analytics agency serving Houston businesses — including sentiment analysis, named entity recognition, document classification. We work with Energy & Oil/Gas, Healthcare & Biotech, Aerospace & Defense companies in Houston, TX via timezone-aligned engineers and async workflows; we do not have a local office, and we are explicit about that with every client.
NLP & Text Analytics in New York, NYZTABS is a remote-first NLP & text analytics agency serving New York businesses — including sentiment analysis, named entity recognition, document classification. We work with Finance & Fintech, Media & Advertising, Fashion & Retail companies in New York, NY via timezone-aligned engineers and async workflows; we do not have a local office, and we are explicit about that with every client.
NLP & Text Analytics in Los Angeles, CAZTABS is a remote-first NLP & text analytics agency serving Los Angeles businesses — including sentiment analysis, named entity recognition, document classification. We work with Entertainment & Media, E-commerce & DTC Brands, Gaming & AR/VR companies in Los Angeles, CA via timezone-aligned engineers and async workflows; we do not have a local office, and we are explicit about that with every client.
Web Development in Seattle, WAZTABS is a remote-first web development agency serving Seattle businesses — including full-stack development, progressive web apps, api development. We work with Cloud Computing, E-commerce & Retail Tech, AI & Machine Learning companies in Seattle, WA via timezone-aligned engineers and async workflows; we do not have a local office, and we are explicit about that with every client.
Web Design in Seattle, WAZTABS is a remote-first web design agency serving Seattle businesses — including ui/ux design, responsive design, custom interfaces. We work with Cloud Computing, E-commerce & Retail Tech, AI & Machine Learning companies in Seattle, WA via timezone-aligned engineers and async workflows; we do not have a local office, and we are explicit about that with every client.
AI Development in Seattle, WAZTABS is a remote-first AI development agency serving Seattle businesses — including llm integration & fine-tuning, ai agents & automation, rag & knowledge systems. We work with Cloud Computing, E-commerce & Retail Tech, AI & Machine Learning companies in Seattle, WA via timezone-aligned engineers and async workflows; we do not have a local office, and we are explicit about that with every client.
NLP & Text AnalyticsLearn more about our NLP & text analytics services nationwide.
Partner with ZTABS for expert NLP & text analytics in Seattle. Get a free consultation today.
